Literature DB >> 16279769

Synthesis, molecular modeling studies, and selective inhibitory activity against monoamine oxidase of 1-thiocarbamoyl-3,5-diaryl-4,5-dihydro-(1H)- pyrazole derivatives.

Franco Chimenti1, Elias Maccioni, Daniela Secci, Adriana Bolasco, Paola Chimenti, Arianna Granese, Olivia Befani, Paola Turini, Stefano Alcaro, Francesco Ortuso, Roberto Cirilli, Francesco La Torre, Maria C Cardia, Simona Distinto.   

Abstract

A novel series of 1-thiocarbamoyl-3,5-diaryl-4,5-dihydro-(1H)-pyrazole derivatives have been synthesized and investigated for the ability to inhibit selectively the activity of the A and B isoforms of monoamine oxidase (MAO). All the synthesized compounds show high activity against both the MAO-A and the MAO-B isoforms with Ki values between 27 and 4 nM and between 50 and 1.5 nM, respectively, except for a few derivatives whose inhibitory activity against MAO-B was in the micromolar range. Knowing that stereochemistry may be an important modulator of biological activity, we performed the semipreparative chromatographic enantioseparation of the most potent, selective, and chiral compounds. The separated enantiomers were then submitted to in vitro biological evaluation. The selectivity of the (-)-(S)-1 enantiomer against MAO-B increases twice and a half, while the selectivity of the (-)-(S)-4 enantiomer against MAO-A triples. Both the MAO-A and MAO-B isoforms respectively of the 1O5W and 1GOS models deposited in the Protein Data Bank were considered in the computational study. The docking study was carried out using several computational approaches with the aim of proposing possible binding modes of the MAO enantioselective compounds 1 and 4.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16279769     DOI: 10.1021/jm040903t

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  Docking of novel reversible monoamine oxidase-B inhibitors: efficient prediction of ligand binding sites and estimation of inhibitors thermodynamic properties.

Authors:  K Yelekçi; O Karahan; M Toprakçi
Journal:  J Neural Transm (Vienna)       Date:  2007-03-31       Impact factor: 3.575

2.  Investigating the Anticancer Activity of Isatin/Dihydropyrazole Hybrids.

Authors:  Rita Meleddu; Vilma Petrikaite; Simona Distinto; Antonella Arridu; Rossella Angius; Lorenzo Serusi; Laura Škarnulytė; Ugnė Endriulaitytė; Miglė Paškevičiu Tė; Filippo Cottiglia; Marco Gaspari; Domenico Taverna; Serenella Deplano; Benedetta Fois; Elias Maccioni
Journal:  ACS Med Chem Lett       Date:  2018-12-18       Impact factor: 4.345

3.  Microwave-assisted green synthesis of 4,5-dihydro-1H-pyrazole-1-carbothioamides in water.

Authors:  Hamid Reza Farmani; Mohammad Hossein Mosslemin; Bahareh Sadeghi
Journal:  Mol Divers       Date:  2018-03-31       Impact factor: 2.943

4.  Evaluation of selective human MAO inhibitory activities of some novel pyrazoline derivatives.

Authors:  Umut Salgin-Gökşen; Samiye Yabanoğlu-Çiftçi; Ayşe Ercan; Kemal Yelekçi; Gülberk Uçar; Nesrin Gökhan-Kelekçi
Journal:  J Neural Transm (Vienna)       Date:  2013-01-30       Impact factor: 3.575

5.  Triazole-dithiocarbamate based selective lysine specific demethylase 1 (LSD1) inactivators inhibit gastric cancer cell growth, invasion, and migration.

Authors:  Yi-Chao Zheng; Ying-Chao Duan; Jin-Lian Ma; Rui-Min Xu; Xiaolin Zi; Wen-Lei Lv; Meng-Meng Wang; Xian-Wei Ye; Shun Zhu; David Mobley; Yan-Yan Zhu; Jun-Wei Wang; Jin-Feng Li; Zhi-Ru Wang; Wen Zhao; Hong-Min Liu
Journal:  J Med Chem       Date:  2013-11-01       Impact factor: 7.446

6.  Through scaffold modification to 3,5-diaryl-4,5-dihydroisoxazoles: new potent and selective inhibitors of monoamine oxidase B.

Authors:  Rita Meleddu; Simona Distinto; Roberto Cirilli; Stefano Alcaro; Matilde Yanez; Maria Luisa Sanna; Angela Corona; Claudia Melis; Giulia Bianco; Peter Matyus; Filippo Cottiglia; Elias Maccioni
Journal:  J Enzyme Inhib Med Chem       Date:  2017-12       Impact factor: 5.051

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.